Archive


Category: BIIB111

  • Biogen’s BIIB111 Fails to Meet its Primary Endpoint in P-III STAR Study for Choroideremia

    Shots: The P-III STAR study involves assessing the safety and efficacy of a single subretinal injection of timrepigene emparvovec (BIIB111/AAV2-REP1) in 169 adult males with a genetically confirmed diagnosis of choroideremia The study did not meet its 1EPs i.e. improvement of at least 15 letters from baseline in BCVA @12mos. post-treatment as measured by the […]